pharma QA – Page 32 – Pharma.Tips

Biologic charge variant shift (CEX) OOS after filling line intervention: data integrity checks for bioassays and analytical similarity packages

“`html Addressing OOS Results from Biologic Charge Variant Shift (CEX) Post-Filling Line Intervention In the highly regulated world of pharmaceutical manufacturing, an out-of-specification (OOS) result stemming from a biologic charge…

Blend uniformity OOS during multi-product campaign: GMP investigation and containment strategy

Managing Blend Uniformity OOS in Multi-Product Campaigns: A GMP Investigation Framework In pharmaceutical manufacturing, maintaining consistency and quality during production is paramount. When out-of-specification (OOS) results regarding blend uniformity arise…

Biologic host cell protein (HCP) OOS after upstream media/raw material change: single-use systems risk controls, leachables review, and supplier oversight actions

Managing OOS for Biologic Host Cell Protein Post Upstream Media Change: Investigation and Solutions In the complex landscape of pharmaceutical manufacturing, deviations such as Out of Specification (OOS) results can…

Stability degradation during CPV review: GMP investigation and containment strategy

“`html Addressing Stability Degradation Observed During CPV Review: A Comprehensive GMP Investigation Stability degradation during the Continuous Process Verification (CPV) review can pose significant hurdles for pharmaceutical manufacturing, especially within…

Biologic cold chain excursion impact during deviation investigation board review: investigation strategy aligned to FDA/EMA expectations and comparability principles

Assessing the Impact of Cold Chain Excursions in Biologics: A Comprehensive Investigation Strategy In the realm of pharmaceutical manufacturing, particularly with biologics, maintaining the integrity of the cold chain is…

Potency variability during CPV review: facility and HVAC risk mitigation

P addressing Potency Variability During CPV Review: Strategies for Risk Mitigation in Facility and HVAC Systems In the pharmaceutical manufacturing landscape, potency variability is a critical issue during Continued Process…

Biologic host cell protein (HCP) OOS during commercial manufacturing campaign: single-use systems risk controls, leachables review, and supplier oversight actions

Comprehensive Investigation of Out-of-Specification Host Cell Protein (HCP) Results in Biologic Manufacturing Biologic manufacturing is a highly complex process where even minor deviations can lead to significant consequences in product…

Cleaning validation failure during multi-product campaign: facility and HVAC risk mitigation

Addressing Cleaning Validation Failures in Multi-Product Campaigns: Risk Mitigation Strategies for Facilities and HVAC Cleaning validation failures during multi-product campaigns can have significant implications for pharmaceutical manufacturers. They not only…

Biologic viral clearance validation gap during PPQ / process validation: how to document root cause when multiple unit operations are involved

Documenting Root Cause for Biologic Viral Clearance Validation Gaps in Process Validation Biologic medicinal products present unique challenges in ensuring safety and efficacy, particularly regarding viral clearance during the process…

Cleaning validation failure during inspection readiness: GMP investigation and containment strategy

Addressing Cleaning Validation Failures During Inspection Readiness: An In-depth GMP Investigation and Containment Strategy In the complex landscape of pharmaceutical manufacturing, the integrity of cleaning validation processes is paramount, especially…

Biologic glycosylation shift (CQAs) outside trend after equipment qualification update: investigation strategy aligned to FDA/EMA expectations and comparability principles

Investigating Biologic Glycosylation Shift (CQAs) Following Equipment Qualification Update In the highly regulated world of pharmaceutical manufacturing, deviations such as a biologic glycosylation shift that deviates from established trends can…

Stability degradation after cleaning cycle change: CAPA aligned to regulatory expectations

Understanding Stability Degradation Following Modifications to Cleaning Cycles In the pharmaceutical manufacturing environment, stability degradation can arise unexpectedly after changes to cleaning cycles. Such incidents carry significant implications for product…